{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:49:25Z","timestamp":1782485365613,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04954-9","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T10:44:20Z","timestamp":1765622660000},"page":"2665-2676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sodium load of novel antibiotics: considerations for nephrologists and clinicians"],"prefix":"10.1007","volume":"58","author":[{"given":"Flavia","family":"Sudano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8784-1552","authenticated-orcid":false,"given":"Rosario","family":"Maccarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3947-1814","authenticated-orcid":false,"given":"Yuri","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-5448","authenticated-orcid":false,"given":"Luca","family":"Di Lullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-1645","authenticated-orcid":false,"given":"Antonio","family":"Bellasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-4776","authenticated-orcid":false,"given":"Leonardo","family":"Spatola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Puliatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2882-4226","authenticated-orcid":false,"given":"Francesco","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-6144","authenticated-orcid":false,"given":"Matthias","family":"Zeiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-3952","authenticated-orcid":false,"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"4954_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2215\/CJN.12141018","volume":"14","author":"Q Qian","year":"2019","unstructured":"Qian Q (2019) Hypernatremia. Clin J Am Soc Nephrol 14:1\u20133. https:\/\/doi.org\/10.2215\/CJN.12141018","journal-title":"Clin J Am Soc Nephrol"},{"key":"4954_CR2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jcrc.2012.11.013","volume":"28","author":"MD Waite","year":"2013","unstructured":"Waite MD, Fuhrman SA, Badawi O, Zuckerman IH, Franey CS (2013) Intensive care unit-acquired hypernatremia is an independent predictor of increased mortality and length of stay. J Crit Care 28:405\u2013412. https:\/\/doi.org\/10.1016\/j.jcrc.2012.11.013","journal-title":"J Crit Care"},{"key":"4954_CR3","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/ndt\/gfz098","volume":"35","author":"C Thongprayoon","year":"2020","unstructured":"Thongprayoon C, Cheungpasitporn W, Yap JQ, Qian Q (2020) Increased mortality risk associated with serum sodium variations and borderline hypo- and hypernatremia in hospitalized adults. Nephrol Dial Transplant 35:1746\u20131752. https:\/\/doi.org\/10.1093\/ndt\/gfz098","journal-title":"Nephrol Dial Transplant"},{"key":"4954_CR4","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s11845-024-03718-1","volume":"193","author":"KM Kollu","year":"2024","unstructured":"Kollu KM, Bas A, Gok F (2024) Effect of fosfomycin-induced hypernatremia on patients\u2019 hospital stay length and survival. Ir J Med Sci 193:2453\u20132459. https:\/\/doi.org\/10.1007\/s11845-024-03718-1","journal-title":"Ir J Med Sci"},{"key":"4954_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/jcph.2420","volume":"64","author":"H Yao","year":"2024","unstructured":"Yao H, Wang Y, Peng Y, Huang Z, Gan G (2024) A real-world pharmacovigilance study of ceftazidime\/avibactam: data mining of the Food and Drug Administration Adverse Event Reporting System Database. J Clin Pharmacol 64:820\u2013827. https:\/\/doi.org\/10.1002\/jcph.2420","journal-title":"J Clin Pharmacol"},{"key":"4954_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrneph.2009.17","volume":"5","author":"R Zietse","year":"2009","unstructured":"Zietse R, Zoutendijk R, Hoorn EJ (2009) Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol 5:193\u2013202. https:\/\/doi.org\/10.1038\/nrneph.2009.17","journal-title":"Nat Rev Nephrol"},{"key":"4954_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics10020140","volume":"10","author":"MG Scoglio","year":"2021","unstructured":"Scoglio MG, Bronz G, Rinoldi PO et al (2021) Electrolyte and acid-base disorders triggered by aminoglycoside or colistin therapy: a systematic review. Antibiotics 10:1\u20139. https:\/\/doi.org\/10.3390\/antibiotics10020140","journal-title":"Antibiotics"},{"key":"4954_CR8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1177\/1060028019890346","volume":"54","author":"AK Lew","year":"2020","unstructured":"Lew AK, Crass RL, Eschenauer G (2020) Evolution of equations for estimating renal function and their application to the dosing of new antimicrobials. Ann Pharmacother 54:496\u2013503. https:\/\/doi.org\/10.1177\/1060028019890346","journal-title":"Ann Pharmacother"},{"key":"4954_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17512433.2021.1901574","volume":"00","author":"M Gatti","year":"2021","unstructured":"Gatti M, Pea F (2021) Expert review of clinical pharmacology pharmacokinetic \/ pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams \/ beta-lactamase inhibitors. Expert Rev Clin Pharmacol 00:1\u201317. https:\/\/doi.org\/10.1080\/17512433.2021.1901574","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4954_CR10","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.3390\/antibiotics11121769","volume":"11","author":"A Corona","year":"2022","unstructured":"Corona A, Cattaneo D (2022) Antibiotic therapy in the critically ill with acute renal failure and renal replacement therapy: a narrative review. Antibiot 11:1769. https:\/\/doi.org\/10.3390\/antibiotics11121769","journal-title":"Antibiot"},{"key":"4954_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3389\/fphar.2020.00786","volume":"11","author":"L Li","year":"2020","unstructured":"Li L, Li X, Xia Y et al (2020) Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Front Pharmacol 11:786. https:\/\/doi.org\/10.3389\/fphar.2020.00786","journal-title":"Front Pharmacol"},{"key":"4954_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.56434\/j.arch.esp.urol.20227506.72","volume":"75","author":"PR P\u00e9rez","year":"2022","unstructured":"P\u00e9rez PR (2022) Fosfomycin: 50 years of a great discovery (1969\u20132019). Arch Esp Urol 75:482\u2013488. https:\/\/doi.org\/10.56434\/j.arch.esp.urol.20227506.72","journal-title":"Arch Esp Urol"},{"key":"4954_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","volume":"23","author":"B Grabein","year":"2017","unstructured":"Grabein B, Graninger W, Rodr\u00edguez Ba\u00f1o J et al (2017) Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 23:363\u2013372. https:\/\/doi.org\/10.1016\/j.cmi.2016.12.005","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"4954_CR14","first-page":"37","volume":"32","author":"I L\u00f3pez-Montesinos","year":"2019","unstructured":"L\u00f3pez-Montesinos I, Horcajada JP (2019) Oral and intravenous fosfomycin in complicated urinary tract infections. Rev Esp Quimioter 32(Suppl 1):37\u201344","journal-title":"Rev Esp Quimioter"},{"key":"4954_CR15","unstructured":"INFECTOPHARM Arzneimittel und Consilium GmbH. Infectofos (fosfomicina): Riassunto delle caratteristiche del prodotto. Germania, rinnovo dell\u2019autorizzazione: gennaio 2019."},{"key":"4954_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","volume":"4","author":"D Iarikov","year":"2015","unstructured":"Iarikov D, Wassel R, Farley J, Nambiar S (2015) Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. Infect Dis Ther 4:433\u2013458. https:\/\/doi.org\/10.1007\/s40121-015-0092-8","journal-title":"Infect Dis Ther"},{"key":"4954_CR17","doi-asserted-by":"publisher","unstructured":"Biscarini S, Mangioni D, Bobbio C et al. Adverse events during intravenous fosfomycin therapy in a real-life scenario. Risk factors and the potential role of therapeutic drug monitoring. BMC Infect Dis 2024; 24: 1\u201311. https:\/\/doi.org\/10.1186\/s12879-024-09541-4.","DOI":"10.1186\/s12879-024-09541-4"},{"key":"4954_CR18","unstructured":"Menarini International Operations Luxembourg S. A. Vaborem (meropenem vaborbactam): Summary of product characteristics. Luxembourg, latest renewal: July 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaborem-epar-product-information_en.pdf."},{"key":"4954_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/14787210.2020.1756775","volume":"18","author":"A Novelli","year":"2020","unstructured":"Novelli A, Del Giacomo P, Rossolini GM, Tumbarello M (2020) Meropenem\/vaborbactam: a next generation \u03b2-lactam \u03b2-lactamase inhibitor combination. Expert Rev Anti Infect Ther 18:643\u2013655. https:\/\/doi.org\/10.1080\/14787210.2020.1756775","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4954_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G et al (2018) Effect and safety of meropenem\u2013vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther 7:439\u2013455. https:\/\/doi.org\/10.1007\/s40121-018-0214-1","journal-title":"Infect Dis Ther"},{"key":"4954_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S et al (2018) Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection the TANGO I randomized clinical trial. JAMA J Am Med Assoc 319:788\u2013799. https:\/\/doi.org\/10.1001\/jama.2018.0438","journal-title":"JAMA J Am Med Assoc"},{"key":"4954_CR22","unstructured":"Merck Sharp & Dohme B.V. Zerbaxa (ceftolozane and tazobactam), Summary of product characteristics. Netherlands, latest renewal: April 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zerbaxa-epar-product-information_en.pdf."},{"key":"4954_CR23","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J, Yuan G (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949\u20131956. https:\/\/doi.org\/10.1016\/S0140-6736(14)62220-0","journal-title":"Lancet"},{"key":"4954_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc et al (2019) Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 19:1299\u20131311. https:\/\/doi.org\/10.1016\/S1473-3099(19)30403-7","journal-title":"Lancet Infect Dis"},{"key":"4954_CR25","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, Hershberger E, Miller B et al (2015) Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60:1462\u20131471. https:\/\/doi.org\/10.1093\/cid\/civ097","journal-title":"Clin Infect Dis"},{"key":"4954_CR26","unstructured":"Shionogi B.V. Fetcroja (cefiderocol): Summary of product characteristics. Netherlands, last updated: January 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fetcroja."},{"key":"4954_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenitsky S et al (2019) Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs 79:271\u2013289. https:\/\/doi.org\/10.1007\/s40265-019-1055-2","journal-title":"Drugs"},{"key":"4954_CR28","doi-asserted-by":"publisher","first-page":"S552","DOI":"10.1093\/cid\/ciz828","volume":"69","author":"T Katsube","year":"2019","unstructured":"Katsube T, Echols R, Wajima T (2019) Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis 69:S552\u2013S558. https:\/\/doi.org\/10.1093\/cid\/ciz828","journal-title":"Clin Infect Dis"},{"key":"4954_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02171-20","volume":"65","author":"EK McCreary","year":"2021","unstructured":"McCreary EK, Heil EL, Tamma PD (2021) New perspectives on antimicrobial agents: cefiderocol. Antimicrob Agents Chemother 65:1\u201314. https:\/\/doi.org\/10.1128\/AAC.02171-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4954_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M et al (2021) Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 21:213\u2013225. https:\/\/doi.org\/10.1016\/S1473-3099(20)30731-3","journal-title":"Lancet Infect Dis"},{"issue":"suppl 1","key":"4954_CR31","doi-asserted-by":"publisher","first-page":"S537","DOI":"10.1093\/ofid\/ofx163.1399","volume":"4","author":"S Portsmouth","year":"2017","unstructured":"Portsmouth S, Van Veenhuyzen D, Echols R et al (2017) Clinical response of cefiderocol compared with imipenem\/cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double-blind, randomised study (APEKS-cUTI). Open Forum Infect Dis 4(suppl 1):S537\u2013S538. https:\/\/doi.org\/10.1093\/ofid\/ofx163.1399","journal-title":"Open Forum Infect Dis"},{"key":"4954_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21:226\u2013240. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9","journal-title":"Lancet Infect Dis"},{"key":"4954_CR33","unstructured":"A. Menarini \u2013 Industrie Farmaceutiche Riunite \u2013 s.r.l. Quofenix (delafloxacin): Summary of product characteristics. Italy, latest renewal: August 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/quofenix-epar-product-information_en.pdf."},{"key":"4954_CR34","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jcph.1099","volume":"58","author":"R Hoover","year":"2018","unstructured":"Hoover R, Alcorn H, Lawrence L et al (2018) Pharmacokinetics of intravenous delafloxacin in patients with end-stage renal disease. J Clin Pharmacol 58:913\u2013919. https:\/\/doi.org\/10.1002\/jcph.1099","journal-title":"J Clin Pharmacol"},{"key":"4954_CR35","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1093\/cid\/ciz006","volume":"68","author":"PA Giordano","year":"2019","unstructured":"Giordano PA, Pogue JM, Cammarata S (2019) Analysis of pooled phase III efficacy data for delafloxacin in acute bacterial skin and skin structure infections. Clin Infect Dis 68:S223\u2013S232. https:\/\/doi.org\/10.1093\/cid\/ciz006","journal-title":"Clin Infect Dis"},{"key":"4954_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/14787210.2021.2020098","volume":"20","author":"M Bassetti","year":"2020","unstructured":"Bassetti M, Melchio M, Giacobbe DR (2020) Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Rev Anti Infect Ther 20:649\u2013656. https:\/\/doi.org\/10.1080\/14787210.2021.2020098","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4954_CR37","doi-asserted-by":"publisher","unstructured":"Merck Sharp & Dohme B.V. Recarbrio (imipenem, cilastatin and relebactam), Summary of product characteristics. Netherlands, last updated: September 2024. https:\/\/doi.org\/10.4337\/9781788973984.00022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf","DOI":"10.4337\/9781788973984.00022"},{"key":"4954_CR38","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","volume":"72","author":"M Sims","year":"2017","unstructured":"Sims M, Mariyanovski V, McLeroth P et al (2017) Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother 72:2616\u20132626. https:\/\/doi.org\/10.1093\/jac\/dkx139","journal-title":"J Antimicrob Chemother"},{"key":"4954_CR39","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/AAC.00633-16","volume":"60","author":"C Lucasti","year":"2016","unstructured":"Lucasti C, Vasile L, Sandesc D et al (2016) Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60:6234\u20136243. https:\/\/doi.org\/10.1128\/AAC.00633-16","journal-title":"Antimicrob Agents Chemother"},{"key":"4954_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02203-19","author":"KS Kaye","year":"2020","unstructured":"Kaye KS, Boucher HW, Brown ML et al (2020) Comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 phase 3 trial of imipenem-cilastatin-relebactam versus colistin plus imipenem-cilastatin in patients with imipenem-nonsusceptible bacterial infections. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02203-19","journal-title":"Antimicrob Agents Chemother"},{"key":"4954_CR41","unstructured":"AstraZeneca AB. Zavicefta (ceftazidime and avibactam): Summary of product characteristics. Ireland, latest renewal: February 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf."},{"key":"4954_CR42","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J et al (2016) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380\u20131389. https:\/\/doi.org\/10.1093\/cid\/ciw133","journal-title":"Clin Infect Dis"},{"key":"4954_CR43","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, Sobel JD, Newell P et al (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63:754\u2013762. https:\/\/doi.org\/10.1093\/cid\/ciw378","journal-title":"Clin Infect Dis"},{"key":"4954_CR44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J et al (2018) Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 18:285\u2013295. https:\/\/doi.org\/10.1016\/S1473-3099(17)30747-8","journal-title":"Lancet Infect Dis"},{"key":"4954_CR45","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ et al (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant enterobacteriaceae and pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed. Lancet Infect Dis 16:661\u2013673. https:\/\/doi.org\/10.1016\/S1473-3099(16)30004-4","journal-title":"Lancet Infect Dis"},{"key":"4954_CR46","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1111\/jcpt.13796","volume":"47","author":"X Guo","year":"2022","unstructured":"Guo X, Guo M, Li J (2022) Central nervous system adverse events of ceftazidime\/avibactam: a retrospective study using Food and Drug Administration Adverse Event Reporting System. J Clin Pharm Ther 47:2369\u20132372. https:\/\/doi.org\/10.1111\/jcpt.13796","journal-title":"J Clin Pharm Ther"},{"key":"4954_CR47","unstructured":"PAION Deutschland GmbH. Xerava (eravacycline): Summary of product characteristics. Germany, latest renewal: April 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xerava-epar-product-information_en.pdf."},{"key":"4954_CR48","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","volume":"38","author":"YR Lee","year":"2019","unstructured":"Lee YR, Burton CE (2019) Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis 38:1787\u20131794. https:\/\/doi.org\/10.1007\/s10096-019-03590-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4954_CR49","doi-asserted-by":"publisher","unstructured":"Venipharm. Xenleta (lefamulin): Summary of product characteristics. France, last updated: April 2025. https:\/\/doi.org\/10.1163\/9789004443310_012. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xenleta-epar-product-information_en.pdf","DOI":"10.1163\/9789004443310_012"},{"key":"4954_CR50","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/cid\/ciz090","volume":"69","author":"TM File","year":"2020","unstructured":"File TM, Goldberg L, Das A et al (2020) Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis 69:1856\u20131867. https:\/\/doi.org\/10.1093\/cid\/ciz090","journal-title":"Clin Infect Dis"},{"key":"4954_CR51","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2019.15468","volume":"322","author":"E Alexander","year":"2019","unstructured":"Alexander E, Goldberg L, Das AF et al (2019) Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA 322:1661\u20131671. https:\/\/doi.org\/10.1001\/jama.2019.15468","journal-title":"JAMA"},{"key":"4954_CR52","unstructured":"Pfizer Ireland Pharmaceuticals Unlimited Company. Zinforo (ceftaroline fosamil): Summary of product characteristics. Ireland, latest renewal: August 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zinforo-epar-product-information_en.pdf."},{"key":"4954_CR53","unstructured":"Merck Sharp & Dohme B.V. Sivextro (tedizolid phosphate): Summary of product characteristics. Netherlands, latest renewal: January 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sivextro-epar-product-information_en.pdf."},{"key":"4954_CR54","unstructured":"Durata Therapeutics International B.V. Xydalba (dalbavancin): Summary of product characteristics. Netherlands, last update: May 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xydalba-epar-product-information_en.pdf."},{"key":"4954_CR55","doi-asserted-by":"publisher","unstructured":"Menarini International Operations Luxembourg S.A. Tenkasi (oritavancin): Summary of product characteristics. Luxembourg, latest renewal: January 2020. https:\/\/doi.org\/10.1163\/9789004443310_012. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tenkasi-epar-product-information_en.pdf","DOI":"10.1163\/9789004443310_012"},{"key":"4954_CR56","unstructured":"European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals, 2016\u20132017. Stockholm: ECDC; 2023. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-5"},{"key":"4954_CR57","unstructured":"Antibiotic resistance threats in the United States, 2019. Atlanta (GA): Centers for Disease Control and Prevention; 2019. https:\/\/stacks.cdc.gov\/view\/cdc\/82532"},{"issue":"13","key":"4954_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21134744","volume":"21","author":"S Borrelli","year":"2020","unstructured":"Borrelli S, Provenzano M, Gagliardi I, Michael A et al (2020) Sodium intake and chronic kidney disease. Int J Mol Sci 21(13):4744. https:\/\/doi.org\/10.3390\/ijms21134744","journal-title":"Int J Mol Sci"},{"key":"4954_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.844122","volume":"13","author":"C Scavone","year":"2022","unstructured":"Scavone C, Mascolo A, Bernardi FF et al (2022) Hypernatremia during intravenous treatment with fosfomycin: a retrospective medical record review study and an analysis of spontaneous reports in the EudraVigilance database. Front Pharmacol 13:1\u20137. https:\/\/doi.org\/10.3389\/fphar.2022.844122","journal-title":"Front Pharmacol"},{"key":"4954_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3727","author":"J Van den Eynde","year":"2025","unstructured":"Van den Eynde J, Verbrugge FH (2025) Water and electrolyte homeostasis during decongestion in heart failure. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3727","journal-title":"Eur J Heart Fail"},{"issue":"3\u20134","key":"4954_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000047396","volume":"96","author":"MA Cadnapaphornchai","year":"2001","unstructured":"Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW (2001) Pathophysiology of sodium and water retention in heart failure. Cardiology 96(3\u20134):122\u2013131. https:\/\/doi.org\/10.1159\/000047396. (PMID: 11805379)","journal-title":"Cardiology"},{"key":"4954_CR62","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2215\/CJN.14381121","volume":"17","author":"S Patel","year":"2022","unstructured":"Patel S (2022) Sepsis management for the nephrologist. Clin J Am Soc Nephrol 17:880\u2013889. https:\/\/doi.org\/10.2215\/CJN.14381121","journal-title":"Clin J Am Soc Nephrol"},{"key":"4954_CR63","unstructured":"Sodium reduction. Geneva: World Health Organization; 2025 Feb 7. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sodium-reduction"},{"key":"4954_CR64","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA \/ ACC \/ HFSA guideline for the management of heart failure\u202f: A report of the American College of Cardiology \/ American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol 79:e263\u2013e421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"4954_CR65","doi-asserted-by":"publisher","unstructured":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24: 4\u2013131. https:\/\/doi.org\/10.1002\/ejhf.2333.","DOI":"10.1002\/ejhf.2333"},{"key":"4954_CR66","doi-asserted-by":"publisher","unstructured":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105(4S): S117-S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"4954_CR67","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","volume":"53","author":"P Gin\u00e8s","year":"2010","unstructured":"Gin\u00e8s P, Paolo A, Kurtet L et al (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53:397\u2013417. https:\/\/doi.org\/10.1016\/j.jhep.2010.05.004","journal-title":"J Hepatol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04954-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04954-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04954-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:18:46Z","timestamp":1782483526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04954-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":67,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4954"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04954-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}